Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MNS 是一种酪氨酸激酶抑制剂和广谱抗血小板药物,是一种 β-硝基苯乙烯衍生物。它完全抑制 U46619 (IC50:2.1 μM)、ADP (IC50:4.1 μM)、花生四烯酸 (IC50:5.8 μM)、胶原 (IC50:7.0 μM)和凝血酶 (IC50:12.7 μM)诱导的血小板聚集,并抑制 Src (IC50:27.3 μM)、Syk (IC50:2.8 μM) 和 FAK (IC50:97.6 μM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
50 mg | ¥ 298 | 现货 | ||
100 mg | ¥ 417 | 现货 | ||
200 mg | ¥ 756 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 287 | 现货 |
产品描述 | MNS is a tyrosine kinases inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively. |
靶点活性 | p97:1.7 μM, Syk:2.5 μM, Src:29.3 μM |
体外活性 | LY3023414 shows high solubility across a wide pH range. In vitro, inhibition of PI3K/AKT/mTOR signaling by LY3023414 causes G1 cell-cycle arrest and resulted in broad antiproliferative activity in cancer cell panel screens. In cell-based assays, LY3023414 inhibition of PI3K and mTOR is assessed in the PTEN-deficient U87 MG glioblastoma cell line. LY3023414 inhibits the phosphorylation of AKT at position T308 downstream of PI3K at an IC50 of 106 nM. Similarly, LY3023414 inhibits phosphorylation of AKT at position S473 (IC50 = 94.2 nM) by mTORC2 as well as phosphorylation of mTORC1 kinase targets p70S6K (position T389; IC50 =10.6 nM) and 4E-BP1 (positions T37/46; IC50 = 187 nM). The downstream phosphorylation of S6RP at positions pS240/244 (IC50 = 19.1 nM) by p70S6K was inhibited as well, indicating target inhibition along the entire PI3K/AKT/mTOR pathway by LY3023414[1]. |
分子量 | 193.16 |
分子式 | C9H7NO4 |
CAS No. | 1485-00-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 19.3 mg/mL (100 mM)
Ethanol: 1 mg/mL (5 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 5.1771 mL | 25.8853 mL | 51.7706 mL | 129.4264 mL |
5 mM | 1.0354 mL | 5.1771 mL | 10.3541 mL | 25.8853 mL | |
DMSO | 10 mM | 0.5177 mL | 2.5885 mL | 5.1771 mL | 12.9426 mL |
20 mM | 0.2589 mL | 1.2943 mL | 2.5885 mL | 6.4713 mL | |
50 mM | 0.1035 mL | 0.5177 mL | 1.0354 mL | 2.5885 mL | |
100 mM | 0.0518 mL | 0.2589 mL | 0.5177 mL | 1.2943 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MNS 1485-00-3 Angiogenesis Tyrosine Kinase/Adaptors Ubiquitination Syk Src p97 thrombin aggregation NSC170724 Inhibitor NSC 170724 activation inhibit NSC-170724 Spleen tyrosine kinase derivative GPIIb/IIIa beta-nitrostyrene platelet inhibitor